MX386771B - Inhibidores de cxcr-2 para tratamiento de trastornos de artropatía por cristales. - Google Patents
Inhibidores de cxcr-2 para tratamiento de trastornos de artropatía por cristales.Info
- Publication number
- MX386771B MX386771B MX2018010946A MX2018010946A MX386771B MX 386771 B MX386771 B MX 386771B MX 2018010946 A MX2018010946 A MX 2018010946A MX 2018010946 A MX2018010946 A MX 2018010946A MX 386771 B MX386771 B MX 386771B
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- cxcr
- inhibitors
- crystal arthropathy
- pyrimidin
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 102100028989 C-X-C chemokine receptor type 2 Human genes 0.000 title 1
- 101710082498 C-X-C chemokine receptor type 2 Proteins 0.000 title 1
- 208000037329 crystal arthropathy Diseases 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- UCCNQCNIPRKLRP-CJNGLKHVSA-N n-[6-[(2r,3s)-3,4-dihydroxybutan-2-yl]oxy-2-[(4-fluorophenyl)methylsulfanyl]pyrimidin-4-yl]-3-methylazetidine-1-sulfonamide Chemical compound N=1C(SCC=2C=CC(F)=CC=2)=NC(O[C@H](C)[C@@H](O)CO)=CC=1NS(=O)(=O)N1CC(C)C1 UCCNQCNIPRKLRP-CJNGLKHVSA-N 0.000 abstract 2
- 102000009410 Chemokine receptor Human genes 0.000 abstract 1
- 108050000299 Chemokine receptor Proteins 0.000 abstract 1
- 102000019034 Chemokines Human genes 0.000 abstract 1
- 108010012236 Chemokines Proteins 0.000 abstract 1
- 201000005569 Gout Diseases 0.000 abstract 1
- 230000009286 beneficial effect Effects 0.000 abstract 1
- 229940126214 compound 3 Drugs 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- QZECRCLSIGFCIO-RISCZKNCSA-N n-[2-[(2,3-difluorophenyl)methylsulfanyl]-6-[(2r,3s)-3,4-dihydroxybutan-2-yl]oxypyrimidin-4-yl]azetidine-1-sulfonamide Chemical compound N=1C(SCC=2C(=C(F)C=CC=2)F)=NC(O[C@H](C)[C@@H](O)CO)=CC=1NS(=O)(=O)N1CCC1 QZECRCLSIGFCIO-RISCZKNCSA-N 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physical Education & Sports Medicine (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662307348P | 2016-03-11 | 2016-03-11 | |
| PCT/US2017/021570 WO2017156270A1 (en) | 2016-03-11 | 2017-03-09 | Cxcr-2 inhibitors for treating crystal arthropathy disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2018010946A MX2018010946A (es) | 2019-05-23 |
| MX386771B true MX386771B (es) | 2025-03-19 |
Family
ID=59789863
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018010946A MX386771B (es) | 2016-03-11 | 2017-03-09 | Inhibidores de cxcr-2 para tratamiento de trastornos de artropatía por cristales. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US10772886B2 (enExample) |
| EP (1) | EP3426253A4 (enExample) |
| JP (2) | JP6883917B2 (enExample) |
| CN (2) | CN113893252A (enExample) |
| AU (1) | AU2017231832B2 (enExample) |
| BR (1) | BR112018068393A2 (enExample) |
| CA (1) | CA3017345A1 (enExample) |
| CO (1) | CO2018010880A2 (enExample) |
| MX (1) | MX386771B (enExample) |
| WO (1) | WO2017156270A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113893252A (zh) | 2016-03-11 | 2022-01-07 | 阿迪亚生命科学公司 | 用于治疗结晶性关节病症的cxcr-2抑制剂 |
| WO2019055509A1 (en) * | 2017-09-12 | 2019-03-21 | Ardea Biosciences, Inc. | INHIBITORS OF CXCR-2 FOR THE TREATMENT OF DISORDERS |
| US11136315B2 (en) | 2018-01-11 | 2021-10-05 | Medshine Discovery Inc. | CXCR2 antagonist |
| WO2021004531A1 (zh) * | 2019-07-11 | 2021-01-14 | 南京明德新药研发有限公司 | 一种cxcr2拮抗剂的晶型及其应用 |
| KR102260478B1 (ko) * | 2019-08-19 | 2021-06-02 | 연세대학교 산학협력단 | 일나트륨 요소화물 결정 용해용 조성물 |
| TW202210068A (zh) * | 2020-06-05 | 2022-03-16 | 美商雅力思提雅治療公司 | 用於治療家族性地中海型發熱病的cxcr-2抑制劑 |
| WO2022162021A1 (en) * | 2021-01-27 | 2022-08-04 | Astrazeneca Ab | Verinurad compositions and methods of use |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0217431D0 (en) | 2002-07-27 | 2002-09-04 | Astrazeneca Ab | Novel compounds |
| KR100883476B1 (ko) | 2004-01-30 | 2009-02-16 | 쉐링 코포레이션 | Ｃｘｃ-케모킨 수용체 리간드의 결정성 다형체 |
| BRPI0514735B8 (pt) | 2004-08-28 | 2021-05-25 | Astrazeneca Ab | derivados de pirimidino sulfonamida como moduladores do receptor de quimiocina. |
| AU2008206231A1 (en) * | 2007-01-19 | 2008-07-24 | Takeda Pharmaceuticals U.S.A., Inc. | Methods for preventing or reducing the number of gout flares using xanthine oxidoreductase inhibitors and anti-inflammatory agents |
| EP2203432A4 (en) | 2007-09-21 | 2011-04-27 | Glaxosmithkline Llc | PROCESSING METHOD |
| US20090093548A1 (en) | 2007-10-05 | 2009-04-09 | Mutual Pharmaceutical Company, Inc | Colchine compositions and methods |
| CA2706883A1 (en) | 2007-12-04 | 2009-06-11 | Schering Corporation | Methods of treating copd |
| KR20110014141A (ko) | 2008-03-20 | 2011-02-10 | 카롤러스 테라퓨틱스, 인코포레이티드 | 염증을 치료하는 방법 |
| CN102159555A (zh) | 2008-07-16 | 2011-08-17 | 阿斯利康(瑞典)有限公司 | 嘧啶基氨磺酰衍生物及其治疗趋化因子介导的疾病的用途 |
| MX2011003328A (es) | 2008-10-06 | 2011-06-20 | Carolus Therapeutics Inc | Metodos para tratar inflamacion. |
| US8298533B2 (en) | 2008-11-07 | 2012-10-30 | Medimmune Limited | Antibodies to IL-1R1 |
| WO2010056399A1 (en) | 2008-11-17 | 2010-05-20 | Incode Biopharmaceutics, Inc. | Method and composition for modulating the immune system and various inflammatory conditions comprising complement depletors |
| US20110256130A1 (en) | 2008-12-01 | 2011-10-20 | Joshua Robert Schultz | Methods of treating inflammatory disorders |
| WO2010071865A1 (en) * | 2008-12-19 | 2010-06-24 | Nuon Therapeutics, Inc. | Pharmaceutical compositions and methods for treating hyperuricemia and related disorders |
| ES2559029T3 (es) | 2009-04-24 | 2016-02-10 | Tissue Tech, Inc. | Composiciones que contienen al complejo HC.HA y metodos de uso de las mismas |
| MX2012003514A (es) | 2009-09-23 | 2012-04-19 | Carolus Therapeutics Inc | Metodos para tratamiento de inflamaciones. |
| WO2011116245A2 (en) | 2010-03-19 | 2011-09-22 | Carolus Therapeutics, Inc. | Methods of treating inflammation |
| WO2012007748A1 (en) | 2010-07-13 | 2012-01-19 | Astrazeneca Ab | New crystalline forms of n-[2-[[(2,3-difluoropheny)methyl)thio]-6-{[(1r,2s)-2,3-dihydroxy-1- methylpropyl]oxy}-4-pyrimidinyl]-1-azetidinesulfonamide |
| EP2608672B1 (en) * | 2010-08-23 | 2020-12-16 | Syntrix Biosystems, Inc. | Aminopyridine- and aminopyrimidinecarboxamides as cxcr2 modulators |
| PH12014500107A1 (en) | 2011-07-12 | 2014-03-03 | Astrazeneca Ab | N- (6- ( (2r,3s) -3,4-dihydroxybutan-2-yloxy) -2- (4 - fluorobenzylthio) pyrimidin- 4 - yl) -3- methylazetidine- 1 - sulfonamide as chemokine receptor modulator |
| JP2015528001A (ja) | 2012-07-11 | 2015-09-24 | ティッシュテック，インク． | Ｈｃ−ｈａ／ｐｔｘ３複合体を含む組成物およびその使用方法 |
| EP3220951A1 (en) | 2014-11-17 | 2017-09-27 | MedImmune Limited | Therapeutic combinations and methods for treating neoplasia |
| US20180221312A1 (en) | 2016-03-11 | 2018-08-09 | Ardea Biosciences, Inc. | Cxcr-2 inhibitors for treating disorders |
| CN113893252A (zh) | 2016-03-11 | 2022-01-07 | 阿迪亚生命科学公司 | 用于治疗结晶性关节病症的cxcr-2抑制剂 |
| WO2019055509A1 (en) | 2017-09-12 | 2019-03-21 | Ardea Biosciences, Inc. | INHIBITORS OF CXCR-2 FOR THE TREATMENT OF DISORDERS |
-
2017
- 2017-03-09 CN CN202111152242.9A patent/CN113893252A/zh active Pending
- 2017-03-09 MX MX2018010946A patent/MX386771B/es unknown
- 2017-03-09 EP EP17764095.0A patent/EP3426253A4/en not_active Withdrawn
- 2017-03-09 AU AU2017231832A patent/AU2017231832B2/en not_active Ceased
- 2017-03-09 US US15/516,465 patent/US10772886B2/en not_active Expired - Fee Related
- 2017-03-09 BR BR112018068393A patent/BR112018068393A2/pt not_active Application Discontinuation
- 2017-03-09 WO PCT/US2017/021570 patent/WO2017156270A1/en not_active Ceased
- 2017-03-09 CN CN201780029205.4A patent/CN109152780B/zh active Active
- 2017-03-09 JP JP2018547929A patent/JP6883917B2/ja not_active Expired - Fee Related
- 2017-03-09 CA CA3017345A patent/CA3017345A1/en active Pending
-
2018
- 2018-10-10 CO CONC2018/0010880A patent/CO2018010880A2/es unknown
-
2021
- 2021-05-05 JP JP2021078242A patent/JP7126014B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| BR112018068393A2 (pt) | 2019-01-15 |
| CA3017345A1 (en) | 2017-09-14 |
| AU2017231832B2 (en) | 2021-11-11 |
| CN109152780B (zh) | 2021-10-01 |
| JP7126014B2 (ja) | 2022-08-25 |
| AU2017231832A1 (en) | 2018-10-04 |
| EP3426253A4 (en) | 2019-11-06 |
| CN113893252A (zh) | 2022-01-07 |
| JP2019507791A (ja) | 2019-03-22 |
| WO2017156270A1 (en) | 2017-09-14 |
| EP3426253A1 (en) | 2019-01-16 |
| JP6883917B2 (ja) | 2021-06-09 |
| MX2018010946A (es) | 2019-05-23 |
| CN109152780A (zh) | 2019-01-04 |
| US20180235964A1 (en) | 2018-08-23 |
| US10772886B2 (en) | 2020-09-15 |
| JP2021121600A (ja) | 2021-08-26 |
| CO2018010880A2 (es) | 2018-10-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2018010880A2 (es) | Inhibidores de cxcr-2 para tratamiento de trastornos de artropatía por cristales | |
| CO2020003061A2 (es) | Inhibidores de cxcr-2 para tratar trastornos | |
| CO2020013155A2 (es) | Moduladores de nlrp3 | |
| EA201990187A1 (ru) | Антипролиферационные средства на основе пиримидина | |
| EA202090019A1 (ru) | Спироциклические индолины в качестве модуляторов il-17 | |
| EP3895717C0 (en) | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING COLORECTAL CANCER, COMPRISING WEISSELLA CIBARIA WIKIM28 AS ACTIVE SUBSTANCE | |
| CL2017002494A1 (es) | Inhibidores de indolamina-2, 3- dioxigenasa para el tratamiento de cancer | |
| EA201790998A1 (ru) | Иммуннорегуляторные агенты | |
| MX2018010176A (es) | Compuesto novedoso de pirimidina condensada o sal del mismo. | |
| EA201790806A1 (ru) | Иммунорегулирующие средства | |
| EA201790992A1 (ru) | Иммунорегуляторные агенты | |
| MX2023000056A (es) | Compuestos tricíclicos de urea como inhibidores de la variante v617f de la cinasa de janus 2 (jak2 v617f). | |
| CO2020000227A2 (es) | Moduladores de nlrp3 | |
| PE20151594A1 (es) | Inhibidores de indolamina 2-3 dioxigenasa | |
| MX2019000588A (es) | Moduladores de la somatostatina y usos de los mismos. | |
| ECSP12012171A (es) | Composiciones farmacéuticas del compuesto espiro-oxindol para administración tópica y sus usos como agentes terapéuticos | |
| MX2021011507A (es) | Compuestos farmaceuticos para el tratamiento de trastornos mediados por complemento. | |
| ECSP14013130A (es) | N-(6-((2r,3s)-3,4-dihidroxibutan-2-iloxi)-2-(4-fluorobenciltio)pirimidin-4-il)-3-metilacetidina-1-sulfonamida como modulador del receptor de quimiocina | |
| ECSP19026702A (es) | Compuestos novedosos para el tratamiento de enfermedades parasitarias | |
| MX2020004666A (es) | Compuestos de pilocarpina con ácido lipoico para el tratamiento de trastornos oculares. | |
| CO2022014499A2 (es) | Moduladores de nlrp3 | |
| MX2021008941A (es) | Moduladores gpr35. | |
| EA201890525A1 (ru) | Кристаллическая форма 2-(2,6-дихлорфенил)-1-[(1s,3r)-3-(гидроксиметил)-5-(3-гидрокси-3-метилбутил)-1-метил-3,4-дигидроизохинолин-2(1h)-ил]этанона для лечения болезни паркинсона | |
| CL2018002074A1 (es) | Composiciones y métodos para tratar infecciones. | |
| EA201991488A1 (ru) | Модуляторы калиевых каналов |